A new mdr2-/- mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer

American Journal of Pathology

Volumn 185, Issue 2, 2015, Pages 325-334

  Ikenaga, Naoki ^a   Liu, Susan B ^a   Sverdlov, Deanna Y ^a   Yoshida, Shuhei ^a   Nasser, Imad ^a   Ke, Qingen ^a   Kang, Peter M ^a   Popov, Yury ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; PROCOLLAGEN; MULTIDRUG RESISTANCE PROTEIN; P-GLYCOPROTEIN 2; TGFB1 PROTEIN, MOUSE; TIMP1 PROTEIN, MOUSE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CELL ACTIVATION; CONGENIC STRAIN; CONTROLLED STUDY; DISEASE COURSE; LIVER CANCER; LIVER FIBROSIS; MOUSE; MOUSE MODEL; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS; ANIMAL; DEFICIENCY; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; CHOLANGITIS, SCLEROSING; DISEASE MODELS, ANIMAL; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; P-GLYCOPROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84922323884     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.10.013     Document Type: Article

References (41)

1. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115: 209-218
2. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669
3. Schuppan D, Afdhal NH: Liver cirrhosis. Lancet 2008, 371:838-851
4. Talwalkar JA, Lindor KD: Primary sclerosing cholangitis. Inflamm Bowel Dis 2005, 11:62-72
5. Friedman SL, Sheppard D, Duffield JS, Violette S: Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013, 5: 167sr161
6. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, Niedobitek G, Goodman SL, Schuppan D: Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50:1501-1511
7. Bissell DM: Therapy for hepatic fibrosis: revisiting the preclinical models. Clin Res Hepatol Gastroenterol 2011, 35:521-525
8. Hillebrandt S, Goos C, Matern S, Lammert F: Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002, 123:2041-2051
9. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F: Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 2005, 37:835-843
10. Shi Z, Wakil AE, Rockey DC: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997, 94:10663-10668
11. Trauner M, Fickert P, Wagner M: MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007, 27:77-98
12. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Borst P: Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462
13. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M: Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127:261-274
14. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC: Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 2004, 39:117-128
15. Mauad TH, van Nieuwkerk CMJ, Dingemans KP, Smit JJM, Schinkel AH, Notenboom RGE, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RPJ, van der Valk MA, Borst P, Offerhaus GJA: Mice with homozygous disruption of the mdr2 P-glycoprotein gene: a novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994, 145:1237-1245
16. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M: Ursodeoxycholic acid aggravates bile infarcts in bile ductligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251
17. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D: Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005, 43:1045-1054
18. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E: Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci (Landmark Ed) 2009, 14:4242-4256
19. Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrie N: ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008, 135:131-141
20. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ: Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disruptedmdr2P-glycoprotein gene. Gastroenterology 1996, 111:165-171
21. Popov Y, Sverdlov DY, Sharma AK, Bhaskar KR, Li S, Freitag TL, Lee J, Dieterich W, Melino G, Schuppan D: Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011, 140:1642-1652
22. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, Krahenbuhl S, Krahenbuhl L, Schuppan D: Macrophagemediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010, 298:G323-G334
23. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D: Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008, 48:453-464
24. Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y: Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993, 17:1113-1123
25. van Nieuwerk CM, Groen AK, Ottenhoff R, van Wijland M, van den Bergh Weerman MA, Tytgat GN, Offerhaus JJ, Oude Elferink RP: The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J Hepatol 1997, 26:138-145
26. Milani S, Herbst H, Schuppan D, Stein H, Surrenti C: Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991, 139:1221-1229
27. Bergman S, Graeme-Cook F, Pitman MB: The usefulness of the reticulin stain in the differential diagnosis of liver nodules on fine-needle aspiration biopsy cell block preparations. Mod Pathol 1997, 10:1258-1264
28. Popov Y: Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? Hepatology 2013, 57:429-431
29. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP: Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808
30. Hillebrandt S, Keppeler H, Roderfeld M, Roeb E, Sauerbruch T, Lammert F: BALB-Abcb4 knockout mice as new model for spontaneous liver fibrogenesis: genetic strain differences determine severity of fibrosis. Hepatology 2005, 42:599A
31. Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stuhler K, Graf J, Roeb E: Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006, 6:6538-6548
32. Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, Zahner D, Graf J, Roeb E: Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice. Hepatology 2010, 51:267-276
33. Blizard DA, Vandenbergh DJ, Jefferson AL, Chatlos CD, Vogler GP, McClearn GE: Effects of periadolescent ethanol exposure on alcohol preference in two BALB substrains. Alcohol 2004, 34:177-185
34. Seetharamaiah GS, Land KJ: Differential susceptibility of BALB/c and BALB/cBy mice to Graves' hyperthyroidism. Thyroid 2006, 16: 651-658
35. Berzigotti A, Seijo S, Reverter E, Bosch J: Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol 2013, 7:141-155
36. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009, 50:923-928
37. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J: Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003, 37:902-908
38. Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, Soriano G, Guarner C, Balanzo J: Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004, 40:757-765
39. Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J: Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006, 101:506-512
40. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, et al; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group: Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012, 143:1244-1252.e1-12
41. Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010, 7:425-436